25 XP   0   0   10

Medigen Biotechnology
Buy, Hold or Sell?

Let's analyse Medigen together

PenkeI guess you are interested in Medigen Biotechnology. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Medigen Biotechnology. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Medigen Biotechnology

I send you an email if I find something interesting about Medigen Biotechnology.

Quick analysis of Medigen (30 sec.)










What can you expect buying and holding a share of Medigen? (30 sec.)

How much money do you get?

How much money do you get?
NT$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
NT$35.86
Expected worth in 1 year
NT$25.32
How sure are you?
42.5%

+ What do you gain per year?

Total Gains per Share
NT$-10.54
Return On Investment
-27.0%

For what price can you sell your share?

Current Price per Share
NT$39.10
Expected price per share
NT$34.85 - NT$45.60
How sure are you?
50%

1. Valuation of Medigen (5 min.)




Live pricePrice per Share (EOD)

NT$39.10

Intrinsic Value Per Share

NT$46.54 - NT$57.62

Total Value Per Share

NT$82.40 - NT$93.48

2. Growth of Medigen (5 min.)




Is Medigen growing?

Current yearPrevious yearGrowGrow %
How rich?$156.4m$218.2m-$41m-23.1%

How much money is Medigen making?

Current yearPrevious yearGrowGrow %
Making money-$4.3m-$5.2m$896.5k20.4%
Net Profit Margin-50.8%-80.3%--

How much money comes from the company's main activities?

3. Financial Health of Medigen (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#306 / 1031

Most Revenue
#300 / 1031

Most Profit
#433 / 1031

Most Efficient
#557 / 1031

What can you expect buying and holding a share of Medigen? (5 min.)

Welcome investor! Medigen's management wants to use your money to grow the business. In return you get a share of Medigen.

What can you expect buying and holding a share of Medigen?

First you should know what it really means to hold a share of Medigen. And how you can make/lose money.

Speculation

The Price per Share of Medigen is NT$39.10. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Medigen.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Medigen, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is NT$35.86. Based on the TTM, the Book Value Change Per Share is NT$-2.64 per quarter. Based on the YOY, the Book Value Change Per Share is NT$0.07 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is NT$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Medigen.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 NT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per Share
Usd Eps-0.07-0.2%-0.03-0.1%-0.02-0.1%-0.020.0%-0.010.0%
Usd Book Value Change Per Share-0.16-0.4%-0.08-0.2%0.000.0%0.020.1%0.010.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.16-0.4%-0.08-0.2%0.000.0%0.020.1%0.010.0%
Usd Price Per Share1.40-1.13-1.27-1.67-2.50-
Price to Earnings Ratio-4.84--13.36--14.15--11.63--6.75-
Price-to-Total Gains Ratio-8.69--23.42-43.42-59.69-7.80-
Price to Book Ratio1.25-0.90-0.82-1.93-3.06-
Price-to-Total Gains Ratio-8.69--23.42-43.42-59.69-7.80-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.22383
Number of shares817
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.080.02
Usd Total Gains Per Share-0.080.02
Gains per Quarter (817 shares)-67.4118.87
Gains per Year (817 shares)-269.6375.47
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-270-28007565
20-539-5500151140
30-809-8200226215
40-1079-10900302290
50-1348-13600377365
60-1618-16300453440
70-1887-19000528515
80-2157-21700604590
90-2427-24400679665
100-2696-27100755740

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%2.010.00.016.7%3.017.00.015.0%3.020.017.07.5%6.020.027.011.3%
Book Value Change Per Share0.04.00.00.0%6.06.00.050.0%10.010.00.050.0%17.023.00.042.5%25.028.00.047.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.053.00.0%
Total Gains per Share0.04.00.00.0%6.06.00.050.0%10.010.00.050.0%17.023.00.042.5%25.028.00.047.2%

Fundamentals of Medigen

About Medigen Biotechnology

Medigen Biotechnology Corp., a biopharmaceutical company, focuses on the development of therapies for liver diseases and cancers in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for esophageal cancer and gastric cancer patients in the United States. Medigen Biotechnology Corp. was founded in 1999 and is headquartered in Taipei, Taiwan.

Fundamental data was last updated by Penke on 2024-03-26 05:00:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Medigen Biotechnology.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Medigen earns for each NT$1 of revenue.

  • Above 10% is considered healthy but always compare Medigen to the Biotechnology industry mean.
  • A Net Profit Margin of -86.8% means that NT$-0.87 for each NT$1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Medigen Biotechnology:

  • The MRQ is -86.8%. The company is making a huge loss. -2
  • The TTM is -50.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-86.8%TTM-50.8%-36.0%
TTM-50.8%YOY-80.3%+29.6%
TTM-50.8%5Y-52.9%+2.1%
5Y-52.9%10Y-38.0%-14.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-86.8%-159.2%+72.4%
TTM-50.8%-202.3%+151.5%
YOY-80.3%-263.0%+182.7%
5Y-52.9%-452.4%+399.5%
10Y-38.0%-589.0%+551.0%
1.1.2. Return on Assets

Shows how efficient Medigen is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Medigen to the Biotechnology industry mean.
  • -3.8% Return on Assets means that Medigen generated NT$-0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Medigen Biotechnology:

  • The MRQ is -3.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.8%TTM-1.6%-2.2%
TTM-1.6%YOY-1.7%+0.1%
TTM-1.6%5Y-1.3%-0.3%
5Y-1.3%10Y-0.9%-0.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.8%-12.5%+8.7%
TTM-1.6%-12.2%+10.6%
YOY-1.7%-11.2%+9.5%
5Y-1.3%-13.3%+12.0%
10Y-0.9%-14.6%+13.7%
1.1.3. Return on Equity

Shows how efficient Medigen is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Medigen to the Biotechnology industry mean.
  • -20.2% Return on Equity means Medigen generated NT$-0.20 for each NT$1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Medigen Biotechnology:

  • The MRQ is -20.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -8.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.2%TTM-8.2%-12.1%
TTM-8.2%YOY-7.2%-0.9%
TTM-8.2%5Y-5.3%-2.8%
5Y-5.3%10Y-3.3%-2.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.2%-16.0%-4.2%
TTM-8.2%-15.8%+7.6%
YOY-7.2%-13.9%+6.7%
5Y-5.3%-18.2%+12.9%
10Y-3.3%-19.1%+15.8%

1.2. Operating Efficiency of Medigen Biotechnology.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Medigen is operating .

  • Measures how much profit Medigen makes for each NT$1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Medigen to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated NT$0.00  for each NT$1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Medigen Biotechnology:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-42.7%+42.7%
TTM-42.7%YOY-111.0%+68.3%
TTM-42.7%5Y-96.8%+54.1%
5Y-96.8%10Y-64.6%-32.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM-42.7%-208.5%+165.8%
YOY-111.0%-280.2%+169.2%
5Y-96.8%-459.9%+363.1%
10Y-64.6%-596.9%+532.3%
1.2.2. Operating Ratio

Measures how efficient Medigen is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.89 means that the operating costs are NT$2.89 for each NT$1 in net sales.

Let's take a look of the Operating Ratio trends of Medigen Biotechnology:

  • The MRQ is 2.891. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.686. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.891TTM2.686+0.206
TTM2.686YOY4.059-1.373
TTM2.6865Y3.012-0.327
5Y3.01210Y1.963+1.050
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8912.817+0.074
TTM2.6863.181-0.495
YOY4.0593.609+0.450
5Y3.0125.554-2.542
10Y1.9637.396-5.433

1.3. Liquidity of Medigen Biotechnology.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Medigen is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.05 means the company has NT$2.05 in assets for each NT$1 in short-term debts.

Let's take a look of the Current Ratio trends of Medigen Biotechnology:

  • The MRQ is 2.053. The company is able to pay all its short-term debts. +1
  • The TTM is 3.429. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.053TTM3.429-1.375
TTM3.429YOY6.878-3.449
TTM3.4295Y3.480-0.051
5Y3.48010Y1.977+1.503
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0533.987-1.934
TTM3.4294.440-1.011
YOY6.8785.569+1.309
5Y3.4806.158-2.678
10Y1.9776.492-4.515
1.3.2. Quick Ratio

Measures if Medigen is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Medigen to the Biotechnology industry mean.
  • A Quick Ratio of 0.94 means the company can pay off NT$0.94 for each NT$1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Medigen Biotechnology:

  • The MRQ is 0.939. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.807. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ0.939TTM1.807-0.868
TTM1.807YOY2.524-0.718
TTM1.8075Y1.281+0.526
5Y1.28110Y0.777+0.503
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9393.653-2.714
TTM1.8074.158-2.351
YOY2.5245.515-2.991
5Y1.2816.012-4.731
10Y0.7776.206-5.429

1.4. Solvency of Medigen Biotechnology.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Medigen assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Medigen to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.41 means that Medigen assets are financed with 41.4% credit (debt) and the remaining percentage (100% - 41.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Medigen Biotechnology:

  • The MRQ is 0.414. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.378. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.414TTM0.378+0.036
TTM0.378YOY0.296+0.082
TTM0.3785Y0.351+0.027
5Y0.35110Y0.301+0.051
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4140.336+0.078
TTM0.3780.330+0.048
YOY0.2960.267+0.029
5Y0.3510.367-0.016
10Y0.3010.378-0.077
1.4.2. Debt to Equity Ratio

Measures if Medigen is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Medigen to the Biotechnology industry mean.
  • A Debt to Equity ratio of 221.8% means that company has NT$2.22 debt for each NT$1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Medigen Biotechnology:

  • The MRQ is 2.218. The company is just not able to pay all its debts with equity.
  • The TTM is 1.890. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.218TTM1.890+0.328
TTM1.890YOY1.241+0.649
TTM1.8905Y1.355+0.535
5Y1.35510Y0.951+0.404
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2180.376+1.842
TTM1.8900.398+1.492
YOY1.2410.334+0.907
5Y1.3550.431+0.924
10Y0.9510.476+0.475

2. Market Valuation of Medigen Biotechnology

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every NT$1 in earnings Medigen generates.

  • Above 15 is considered overpriced but always compare Medigen to the Biotechnology industry mean.
  • A PE ratio of -4.84 means the investor is paying NT$-4.84 for every NT$1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Medigen Biotechnology:

  • The EOD is -4.228. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.844. Based on the earnings, the company is expensive. -2
  • The TTM is -13.357. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.228MRQ-4.844+0.616
MRQ-4.844TTM-13.357+8.512
TTM-13.357YOY-14.155+0.798
TTM-13.3575Y-11.630-1.727
5Y-11.63010Y-6.753-4.877
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.228-2.697-1.531
MRQ-4.844-2.422-2.422
TTM-13.357-2.709-10.648
YOY-14.155-4.116-10.039
5Y-11.630-6.257-5.373
10Y-6.753-6.478-0.275
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Medigen Biotechnology:

  • The EOD is -183.276. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -209.994. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -75.412. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-183.276MRQ-209.994+26.718
MRQ-209.994TTM-75.412-134.583
TTM-75.412YOY-0.093-75.319
TTM-75.4125Y-19.357-56.054
5Y-19.35710Y-9.679-9.679
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-183.276-3.344-179.932
MRQ-209.994-2.939-207.055
TTM-75.412-3.486-71.926
YOY-0.093-5.592+5.499
5Y-19.357-8.464-10.893
10Y-9.679-8.872-0.807
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Medigen is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.25 means the investor is paying NT$1.25 for each NT$1 in book value.

Let's take a look of the Price to Book Ratio trends of Medigen Biotechnology:

  • The EOD is 1.090. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.249. Based on the equity, the company is underpriced. +1
  • The TTM is 0.903. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.090MRQ1.249-0.159
MRQ1.249TTM0.903+0.346
TTM0.903YOY0.820+0.083
TTM0.9035Y1.929-1.026
5Y1.92910Y3.060-1.131
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.0902.198-1.108
MRQ1.2492.042-0.793
TTM0.9032.121-1.218
YOY0.8202.907-2.087
5Y1.9293.682-1.753
10Y3.0604.114-1.054
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Medigen Biotechnology compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---5.154-2.636-49%0.074-7098%0.738-799%0.346-1589%
Book Value Per Share--35.86140.624-12%50.027-28%34.176+5%29.516+21%
Current Ratio--2.0533.429-40%6.878-70%3.480-41%1.977+4%
Debt To Asset Ratio--0.4140.378+9%0.296+40%0.351+18%0.301+38%
Debt To Equity Ratio--2.2181.890+17%1.241+79%1.355+64%0.951+133%
Dividend Per Share----0%-0%-0%-0%
Eps---2.312-1.012-56%-0.750-68%-0.584-75%-0.362-84%
Free Cash Flow Per Share---0.053-0.978+1734%-2.313+4237%-1.027+1825%-1.027+1825%
Free Cash Flow To Equity Per Share---0.053-0.672+1159%3.834-101%1.772-103%1.772-103%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.575+74%
Intrinsic Value_10Y_max--57.616--------
Intrinsic Value_10Y_min--46.542--------
Intrinsic Value_1Y_max---2.156--------
Intrinsic Value_1Y_min---2.122--------
Intrinsic Value_3Y_max---0.435--------
Intrinsic Value_3Y_min---0.537--------
Intrinsic Value_5Y_max--8.572--------
Intrinsic Value_5Y_min--7.437--------
Market Cap5448428600.000-15%6242712224.0005032039363.938+24%5662847575.000+10%7455076077.788-16%11148060903.894-44%
Net Profit Margin---0.868-0.508-42%-0.803-7%-0.529-39%-0.380-56%
Operating Margin----0.4270%-1.1100%-0.9680%-0.6460%
Operating Ratio--2.8912.686+8%4.059-29%3.012-4%1.963+47%
Pb Ratio1.090-15%1.2490.903+38%0.820+52%1.929-35%3.060-59%
Pe Ratio-4.228+13%-4.844-13.357+176%-14.155+192%-11.630+140%-6.753+39%
Price Per Share39.100-15%44.80036.100+24%40.625+10%53.495-16%80.000-44%
Price To Free Cash Flow Ratio-183.276+13%-209.994-75.412-64%-0.093-100%-19.357-91%-9.679-95%
Price To Total Gains Ratio-7.586+13%-8.692-23.416+169%43.416-120%59.686-115%7.804-211%
Quick Ratio--0.9391.807-48%2.524-63%1.281-27%0.777+21%
Return On Assets---0.038-0.016-58%-0.017-55%-0.013-65%-0.009-77%
Return On Equity---0.202-0.082-60%-0.072-64%-0.053-74%-0.033-84%
Total Gains Per Share---5.154-2.636-49%0.074-7098%0.738-799%0.346-1589%
Usd Book Value--156410137.700177251227.050-12%218275166.750-28%149091374.510+5%128750544.453+21%
Usd Book Value Change Per Share---0.161-0.083-49%0.002-7098%0.023-799%0.011-1589%
Usd Book Value Per Share--1.1221.272-12%1.566-28%1.070+5%0.924+21%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.072-0.032-56%-0.023-68%-0.018-75%-0.011-84%
Usd Free Cash Flow---232621.600-4267911.500+1735%-10091033.925+4238%-3582795.190+1440%-1791397.595+670%
Usd Free Cash Flow Per Share---0.002-0.031+1734%-0.072+4237%-0.032+1825%-0.032+1825%
Usd Free Cash Flow To Equity Per Share---0.002-0.021+1159%0.120-101%0.055-103%0.055-103%
Usd Market Cap170535815.180-15%195396892.611157502832.091+24%177247129.098+10%233343881.235-16%348934306.292-44%
Usd Price Per Share1.224-15%1.4021.130+24%1.272+10%1.674-16%2.504-44%
Usd Profit---10083639.300-4392141.200-56%-5288714.050-48%-2947561.690-71%-1780702.385-82%
Usd Revenue--11613082.5009059159.000+28%8262785.275+41%11430079.225+2%7279890.155+60%
Usd Total Gains Per Share---0.161-0.083-49%0.002-7098%0.023-799%0.011-1589%
 EOD+3 -5MRQTTM+11 -21YOY+9 -235Y+11 -2110Y+13 -20

3.2. Fundamental Score

Let's check the fundamental score of Medigen Biotechnology based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.228
Price to Book Ratio (EOD)Between0-11.090
Net Profit Margin (MRQ)Greater than0-0.868
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.939
Current Ratio (MRQ)Greater than12.053
Debt to Asset Ratio (MRQ)Less than10.414
Debt to Equity Ratio (MRQ)Less than12.218
Return on Equity (MRQ)Greater than0.15-0.202
Return on Assets (MRQ)Greater than0.05-0.038
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Medigen Biotechnology based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.449
Ma 20Greater thanMa 5039.328
Ma 50Greater thanMa 10040.726
Ma 100Greater thanMa 20045.401
OpenGreater thanClose38.850
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in TWD. All numbers in thousands.

Summary
Total Assets8,527,245
Total Liabilities3,530,116
Total Stockholder Equity1,591,643
 As reported
Total Liabilities 3,530,116
Total Stockholder Equity+ 1,591,643
Total Assets = 8,527,245

Assets

Total Assets8,527,245
Total Current Assets5,708,037
Long-term Assets2,819,208
Total Current Assets
Cash And Cash Equivalents 2,222,926
Short-term Investments 2,389,998
Net Receivables 220,125
Inventory 546,906
Other Current Assets 106,318
Total Current Assets  (as reported)5,708,037
Total Current Assets  (calculated)5,486,273
+/- 221,764
Long-term Assets
Property Plant Equipment 2,043,208
Long-term Assets Other 25,640
Long-term Assets  (as reported)2,819,208
Long-term Assets  (calculated)2,068,848
+/- 750,360

Liabilities & Shareholders' Equity

Total Current Liabilities2,779,891
Long-term Liabilities750,225
Total Stockholder Equity1,591,643
Total Current Liabilities
Short Long Term Debt 2,177,710
Accounts payable 75,867
Other Current Liabilities 15,500
Total Current Liabilities  (as reported)2,779,891
Total Current Liabilities  (calculated)2,269,077
+/- 510,814
Long-term Liabilities
Long term Debt 449,099
Capital Lease Obligations Min Short Term Debt284,853
Long-term Liabilities Other 10,280
Long-term Liabilities  (as reported)750,225
Long-term Liabilities  (calculated)744,232
+/- 5,993
Total Stockholder Equity
Total Stockholder Equity (as reported)1,591,643
Total Stockholder Equity (calculated)0
+/- 1,591,643
Other
Capital Stock1,394,748
Common Stock Shares Outstanding 139,346
Net Debt 403,883
Net Invested Capital 4,218,452
Net Working Capital 2,928,146
Property Plant and Equipment Gross 2,043,208



Balance Sheet

Currency in TWD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-06-302009-06-302008-06-302008-03-312007-06-302006-06-302005-06-302004-06-302003-06-30
> Total Assets 
807,049
856,747
718,293
675,347
655,284
665,041
689,158
612,088
721,671
828,579
895,698
880,783
1,214,603
1,059,537
1,729,166
1,718,264
2,240,482
2,135,615
2,137,002
3,095,176
3,294,325
4,337,879
4,231,396
4,620,194
4,463,426
4,309,442
4,320,187
4,412,882
4,494,435
4,994,177
4,793,693
4,781,752
4,822,311
4,636,195
4,673,817
4,893,191
4,846,307
4,630,861
4,945,464
4,773,786
4,598,245
4,654,425
4,760,473
4,538,381
4,828,800
5,033,047
4,807,742
4,854,982
6,152,426
6,217,834
7,007,014
7,395,798
8,199,494
8,151,170
11,012,708
10,742,373
9,982,274
9,481,190
9,259,865
9,120,883
8,527,245
8,527,2459,120,8839,259,8659,481,1909,982,27410,742,37311,012,7088,151,1708,199,4947,395,7987,007,0146,217,8346,152,4264,854,9824,807,7425,033,0474,828,8004,538,3814,760,4734,654,4254,598,2454,773,7864,945,4644,630,8614,846,3074,893,1914,673,8174,636,1954,822,3114,781,7524,793,6934,994,1774,494,4354,412,8824,320,1874,309,4424,463,4264,620,1944,231,3964,337,8793,294,3253,095,1762,137,0022,135,6152,240,4821,718,2641,729,1661,059,5371,214,603880,783895,698828,579721,671612,088689,158665,041655,284675,347718,293856,747807,049
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,716,313
1,577,180
1,556,649
1,298,864
1,247,226
989,312
1,312,122
1,556,944
1,388,336
1,477,004
3,021,684
3,027,144
3,719,858
4,098,233
4,918,282
4,697,986
7,482,739
7,265,309
6,732,826
6,255,283
6,137,068
6,069,588
5,708,037
5,708,0376,069,5886,137,0686,255,2836,732,8267,265,3097,482,7394,697,9864,918,2824,098,2333,719,8583,027,1443,021,6841,477,0041,388,3361,556,9441,312,122989,3121,247,2261,298,8641,556,6491,577,1801,716,31300000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,342,096
641,444
568,553
528,816
490,495
497,885
813,692
785,429
487,275
825,662
2,206,575
933,996
1,526,233
1,574,406
2,144,580
2,045,812
5,170,124
1,877,161
2,040,633
1,714,090
1,473,489
1,262,409
2,222,926
2,222,9261,262,4091,473,4891,714,0902,040,6331,877,1615,170,1242,045,8122,144,5801,574,4061,526,233933,9962,206,575825,662487,275785,429813,692497,885490,495528,816568,553641,4441,342,09600000000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,882
550,824
544,035
374,059
404,653
133,404
102,421
391,778
394,392
62,089
54,200
1,153,640
561,167
365,616
853,599
854,575
53,757
3,048,245
3,136,931
3,189,775
3,208,084
3,230,383
2,389,998
2,389,9983,230,3833,208,0843,189,7753,136,9313,048,24553,757854,575853,599365,616561,1671,153,64054,20062,089394,392391,778102,421133,404404,653374,059544,035550,8248,88200000000000000000000000000000000000000
       Net Receivables 
0
0
0
19,733
1,424
62,404
9,009
3,152
18,286
18,076
23,142
15,749
79,563
35,328
35,612
23,937
129,391
121,035
132,267
74,143
71,686
136,450
87,018
83,154
78,300
84,829
87,415
77,014
82,909
83,373
73,815
78,749
68,603
67,768
72,900
67,244
97,797
88,648
88,157
105,876
93,032
47,965
61,319
64,947
151,248
125,683
169,180
123,052
281,720
337,927
332,203
720,094
811,508
668,155
686,855
689,714
269,634
68,153
306,029
181,764
220,125
220,125181,764306,02968,153269,634689,714686,855668,155811,508720,094332,203337,927281,720123,052169,180125,683151,24864,94761,31947,96593,032105,87688,15788,64897,79767,24472,90067,76868,60378,74973,81583,37382,90977,01487,41584,82978,30083,15487,018136,45071,68674,143132,267121,035129,39123,93735,61235,32879,56315,74923,14218,07618,2863,1529,00962,4041,42419,733000
       Inventory 
0
0
0
0
0
11,940
11,942
16,713
16,346
45,170
39,202
57,792
41,436
48,728
49,886
49,618
26,612
18,233
18,229
11,761
14,203
103,390
89,906
94,649
100,777
97,481
94,179
109,560
128,122
142,431
148,781
139,427
120,806
114,241
105,827
127,023
139,487
138,267
139,381
142,363
130,836
120,252
120,647
135,232
135,265
133,885
186,918
289,018
323,290
324,896
966,956
1,009,377
752,874
779,613
911,492
902,267
692,615
699,503
1,039,079
999,437
546,906
546,906999,4371,039,079699,503692,615902,267911,492779,613752,8741,009,377966,956324,896323,290289,018186,918133,885135,265135,232120,647120,252130,836142,363139,381138,267139,487127,023105,827114,241120,806139,427148,781142,431128,122109,56094,17997,481100,77794,64989,906103,39014,20311,76118,22918,23326,61249,61849,88648,72841,43657,79239,20245,17016,34616,71311,94211,94000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,355,561
3,513,247
3,549,069
3,516,678
3,476,103
3,419,406
3,377,978
3,130,742
3,190,690
3,287,156
3,297,565
3,281,212
3,453,184
3,529,969
3,477,064
3,249,448
3,225,907
3,122,797
3,051,295
2,819,208
2,819,2083,051,2953,122,7973,225,9073,249,4483,477,0643,529,9693,453,1843,281,2123,297,5653,287,1563,190,6903,130,7423,377,9783,419,4063,476,1033,516,6783,549,0693,513,2473,355,56100000000000000000000000000000000000000000
       Property Plant Equipment 
15,415
11,252
5,295
10,187
10,494
30,580
43,504
53,850
84,860
72,491
70,332
78,160
87,728
90,789
99,387
256,219
179,789
181,874
245,821
248,415
570,278
1,005,516
1,191,162
1,307,333
1,487,309
1,599,871
1,611,129
1,655,071
1,913,126
2,120,737
2,229,399
2,276,776
2,375,048
2,392,226
2,367,038
2,353,799
2,353,561
2,320,180
2,309,190
2,287,623
2,234,050
2,553,279
2,513,526
2,533,483
2,540,271
2,500,290
2,498,728
2,466,562
2,166,035
2,160,529
2,147,713
2,126,537
2,189,331
2,263,516
2,249,188
2,214,458
2,197,684
2,175,791
2,153,731
2,121,881
2,043,208
2,043,2082,121,8812,153,7312,175,7912,197,6842,214,4582,249,1882,263,5162,189,3312,126,5372,147,7132,160,5292,166,0352,466,5622,498,7282,500,2902,540,2712,533,4832,513,5262,553,2792,234,0502,287,6232,309,1902,320,1802,353,5612,353,7992,367,0382,392,2262,375,0482,276,7762,229,3992,120,7371,913,1261,655,0711,611,1291,599,8711,487,3091,307,3331,191,1621,005,516570,278248,415245,821181,874179,789256,21999,38790,78987,72878,16070,33272,49184,86053,85043,50430,58010,49410,1875,29511,25215,415
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21,451
21,451
21,451
21,451
97,626
97,626
97,626
97,626
97,626
97,626
97,626
97,626
198,546
96,368
96,264
92,712
92,712
92,712
92,712
92,712
92,712
92,712
92,712
80,466
80,466
76,175
76,175
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000076,17576,17580,46680,46692,71292,71292,71292,71292,71292,71292,71292,71296,26496,368198,54697,62697,62697,62697,62697,62697,62697,62697,62621,45121,45121,45121,45100000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,529
17,487
26,925
24,152
261,855
240,594
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000240,594261,85524,15226,92517,48717,52900000000000000000000000000000000000000
       Intangible Assets 
488,811
361,610
316,589
278,531
17,940
133,863
132,505
152,486
125,426
125,391
136,456
155,107
152,648
148,899
148,065
191,749
186,283
182,957
179,285
175,820
172,247
381,044
378,931
376,235
370,091
363,052
354,277
345,618
337,471
590,541
492,018
352,684
338,684
325,869
322,607
309,724
297,972
258,513
156,893
148,050
138,896
130,127
121,774
113,084
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000113,084121,774130,127138,896148,050156,893258,513297,972309,724322,607325,869338,684352,684492,018590,541337,471345,618354,277363,052370,091376,235378,931381,044172,247175,820179,285182,957186,283191,749148,065148,899152,648155,107136,456125,391125,426152,486132,505133,86317,940278,531316,589361,610488,811
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
43,558
44,347
86,833
53,260
73,541
61,130
71,049
97,024
74,205
94,400
135,787
81,745
56,582
111,769
137,011
113,776
121,294
5,685
11,693
25,640
25,64011,6935,685121,294113,776137,011111,76956,58281,745135,78794,40074,20597,02471,04961,13073,54153,26086,83344,34743,55800000000000000000000000000000000000000000
> Total Liabilities 
6,885
62,989
48,470
68,143
75,190
198,646
207,840
98,694
150,170
45,081
167,510
181,598
298,809
191,705
95,777
116,137
186,417
166,022
225,457
302,093
226,836
558,026
681,089
819,356
804,404
816,365
937,213
1,074,302
1,030,249
1,092,456
1,148,151
1,061,687
1,284,593
1,255,212
1,421,561
1,441,437
1,666,068
1,568,169
1,490,283
1,500,385
1,657,251
1,842,895
1,866,154
1,834,734
2,143,533
2,140,470
2,107,481
2,145,006
1,652,956
1,677,926
2,445,479
2,100,842
1,773,390
1,693,017
3,488,007
3,301,650
3,511,261
3,343,189
3,458,443
3,405,521
3,530,116
3,530,1163,405,5213,458,4433,343,1893,511,2613,301,6503,488,0071,693,0171,773,3902,100,8422,445,4791,677,9261,652,9562,145,0062,107,4812,140,4702,143,5331,834,7341,866,1541,842,8951,657,2511,500,3851,490,2831,568,1691,666,0681,441,4371,421,5611,255,2121,284,5931,061,6871,148,1511,092,4561,030,2491,074,302937,213816,365804,404819,356681,089558,026226,836302,093225,457166,022186,417116,13795,777191,705298,809181,598167,51045,081150,17098,694207,840198,64675,19068,14348,47062,9896,885
   > Total Current Liabilities 
4,507
59,885
6,854
6,588
7,042
147,427
159,389
96,318
143,088
36,458
154,048
174,776
293,815
186,801
91,531
97,338
141,448
93,399
153,518
232,001
210,908
489,564
544,451
594,056
558,351
489,826
319,086
564,008
333,171
400,034
385,777
328,767
547,464
537,117
579,872
626,119
768,262
688,976
448,898
477,671
665,111
540,909
586,314
587,967
930,455
960,685
931,329
976,568
933,802
967,601
1,711,230
1,378,613
1,064,905
902,219
1,032,456
839,154
1,052,323
884,274
2,681,074
2,640,806
2,779,891
2,779,8912,640,8062,681,074884,2741,052,323839,1541,032,456902,2191,064,9051,378,6131,711,230967,601933,802976,568931,329960,685930,455587,967586,314540,909665,111477,671448,898688,976768,262626,119579,872537,117547,464328,767385,777400,034333,171564,008319,086489,826558,351594,056544,451489,564210,908232,001153,51893,399141,44897,33891,531186,801293,815174,776154,04836,458143,08896,318159,389147,4277,0426,5886,85459,8854,507
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
125,950
115,478
117,687
205,806
260,229
226,485
456,197
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000456,197226,485260,229205,806117,687115,478125,95000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
125,950
115,478
117,687
205,806
260,229
226,485
456,197
516,684
537,698
563,127
519,388
447,411
396,258
409,655
344,494
265,681
268,743
284,539
391,633
405,774
2,138,547
2,097,995
2,177,710
2,177,7102,097,9952,138,547405,774391,633284,539268,743265,681344,494409,655396,258447,411519,388563,127537,698516,684456,197226,485260,229205,806117,687115,478125,95000000000000000000000000000000000000000
       Accounts payable 
434
3,147
2,370
932
1,399
8,812
8,726
9,711
6,902
5,190
5,276
5,913
23,292
10,737
6,381
5,654
10,289
7,761
2,177
6,353
8,720
51,092
47,389
83,314
59,623
71,394
51,677
64,360
69,025
88,506
75,155
51,832
48,367
49,356
62,389
79,579
90,708
72,876
75,878
75,450
61,248
23,837
33,733
38,912
107,716
81,593
101,832
143,418
110,001
111,374
131,814
179,730
163,936
160,668
216,781
156,362
150,238
69,262
127,079
48,386
75,867
75,86748,386127,07969,262150,238156,362216,781160,668163,936179,730131,814111,374110,001143,418101,83281,593107,71638,91233,73323,83761,24875,45075,87872,87690,70879,57962,38949,35648,36751,83275,15588,50669,02564,36051,67771,39459,62383,31447,38951,0928,7206,3532,1777,76110,2895,6546,38110,73723,2925,9135,2765,1906,9029,7118,7268,8121,3999322,3703,147434
       Other Current Liabilities 
4,073
6,738
4,484
5,656
5,643
122,451
113,191
42,856
18,088
16,568
14,380
20,904
70,830
14,558
27,748
29,661
131,159
85,638
74,623
98,922
77,188
113,472
124,297
107,961
145,929
64,860
58,914
62,668
120,190
145,240
146,964
88,217
120,048
96,110
111,086
116,099
151,967
113,896
102,070
136,743
201,176
123,531
119,261
112,522
325,385
284,112
236,464
239,257
324,387
433,867
1,228,098
811,843
576,312
474,569
560,512
420,540
24,541
45,261
444,081
13,258
15,500
15,50013,258444,08145,26124,541420,540560,512474,569576,312811,8431,228,098433,867324,387239,257236,464284,112325,385112,522119,261123,531201,176136,743102,070113,896151,967116,099111,08696,110120,04888,217146,964145,240120,19062,66858,91464,860145,929107,961124,297113,47277,18898,92274,62385,638131,15929,66127,74814,55870,83020,90414,38016,56818,08842,856113,191122,4515,6435,6564,4846,7384,073
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,301,986
1,279,840
1,246,767
1,213,078
1,179,785
1,176,152
1,168,438
719,154
710,325
734,249
722,229
708,485
790,798
2,455,551
2,462,496
2,458,938
2,458,915
777,369
764,715
750,225
750,225764,715777,3692,458,9152,458,9382,462,4962,455,551790,798708,485722,229734,249710,325719,1541,168,4381,176,1521,179,7851,213,0781,246,7671,279,8401,301,98600000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-125,950
-115,478
-117,687
144,930
88,827
119,724
-111,275
341,871
350,895
356,790
198,689
197,635
203,520
201,857
199,955
300,202
296,193
292,849
288,445
284,196
294,082
289,618
284,853
284,853289,618294,082284,196288,445292,849296,193300,202199,955201,857203,520197,635198,689356,790350,895341,871-111,275119,72488,827144,930-117,687-115,478-125,95000000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
560
600
600
2,130
2,580
5,000
10,564
7,624
7,625
18,815
17,382
15,894
17,717
12,089
11,355
10,280
10,280
10,280
10,280
10,280
10,28010,28010,28010,28010,28011,35512,08917,71715,89417,38218,8157,6257,62410,5645,0002,5802,13060060056000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
40
10
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000104000000000000000000000000000000000000000
> Total Stockholder Equity
800,164
793,758
669,823
607,204
568,797
446,731
462,167
513,394
525,493
744,063
694,278
665,021
883,237
841,596
1,609,274
1,582,057
1,991,345
1,911,407
1,819,080
2,719,399
2,834,033
3,378,265
3,164,802
3,011,890
2,886,637
2,755,675
2,672,754
2,603,332
2,494,168
2,536,389
2,395,273
2,308,751
2,201,406
2,093,466
2,004,175
1,987,050
1,837,389
1,795,890
1,828,682
1,729,633
1,537,264
1,512,024
1,585,177
1,497,592
1,361,109
1,364,669
1,348,847
1,438,328
1,815,418
1,891,038
1,959,066
2,147,305
2,394,388
2,477,324
2,524,179
2,543,341
2,194,027
1,970,831
1,901,236
1,864,012
1,591,643
1,591,6431,864,0121,901,2361,970,8312,194,0272,543,3412,524,1792,477,3242,394,3882,147,3051,959,0661,891,0381,815,4181,438,3281,348,8471,364,6691,361,1091,497,5921,585,1771,512,0241,537,2641,729,6331,828,6821,795,8901,837,3891,987,0502,004,1752,093,4662,201,4062,308,7512,395,2732,536,3892,494,1682,603,3322,672,7542,755,6752,886,6373,011,8903,164,8023,378,2652,834,0332,719,3991,819,0801,911,4071,991,3451,582,0571,609,274841,596883,237665,021694,278744,063525,493513,394462,167446,731568,797607,204669,823793,758800,164
   Common Stock
762,618
752,265
752,265
752,265
600,500
652,520
662,005
716,900
803,150
965,009
965,408
965,408
1,098,335
1,106,743
1,286,743
1,286,743
1,286,743
1,286,743
1,286,743
1,286,743
1,366,743
1,386,743
1,386,743
1,386,855
1,386,856
1,386,856
1,386,856
1,386,856
1,386,856
1,386,856
1,386,856
1,386,856
1,386,856
1,386,856
1,386,856
1,386,856
1,386,856
1,386,856
1,386,856
1,386,856
1,386,856
1,386,856
1,386,856
1,386,856
1,389,856
1,389,856
1,389,856
1,389,856
1,389,856
1,390,985
1,390,985
1,392,575
1,393,625
1,393,725
1,394,125
1,394,463
0
0
1,393,463
0
0
001,393,463001,394,4631,394,1251,393,7251,393,6251,392,5751,390,9851,390,9851,389,8561,389,8561,389,8561,389,8561,389,8561,386,8561,386,8561,386,8561,386,8561,386,8561,386,8561,386,8561,386,8561,386,8561,386,8561,386,8561,386,8561,386,8561,386,8561,386,8561,386,8561,386,8561,386,8561,386,8561,386,8561,386,8551,386,7431,386,7431,366,7431,286,7431,286,7431,286,7431,286,7431,286,7431,286,7431,106,7431,098,335965,408965,408965,009803,150716,900662,005652,520600,500752,265752,265752,265762,618
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000000000000000000000000000000000
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-13,990
-15,308
-8,029
8,140
-3,547
-7,709
-25,973
-33,676
-54,124
-50,750
-44,371
-43,853
-47,531
-47,606
-54,959
-43,300
-29,644
-31,648
0
0
-31,851
0
0
00-31,85100-31,648-29,644-43,300-54,959-47,606-47,531-43,853-44,371-50,750-54,124-33,676-25,973-7,709-3,5478,140-8,029-15,308-13,99000000000000000000000000000000000000000



Balance Sheet

Currency in TWD. All numbers in thousands.




Cash Flow

Currency in TWD. All numbers in thousands.




Income Statement

Currency in TWD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,157,720
Cost of Revenue-540,391
Gross Profit617,329617,329
 
Operating Income (+$)
Gross Profit617,329
Operating Expense-2,376,370
Operating Income-1,218,650-1,759,041
 
Operating Expense (+$)
Research Development1,336,337
Selling General Administrative499,642
Selling And Marketing Expenses-
Operating Expense2,376,3701,835,979
 
Net Interest Income (+$)
Interest Income89,068
Interest Expense-55,859
Other Finance Cost-0
Net Interest Income33,209
 
Pretax Income (+$)
Operating Income-1,218,650
Net Interest Income33,209
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-1,278,860-1,218,650
EBIT - interestExpense = -55,859
-561,296
-505,437
Interest Expense55,859
Earnings Before Interest and Taxes (EBIT)--1,223,001
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-1,278,860
Tax Provision-191,207
Net Income From Continuing Ops-1,470,067-1,470,067
Net Income-561,296
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--33,209
 

Technical Analysis of Medigen
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Medigen. The general trend of Medigen is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Medigen's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Medigen Biotechnology.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 43.40 < 44.05 < 45.60.

The bearish price targets are: 36.30 > 34.90 > 34.85.

Tweet this
Medigen Biotechnology Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Medigen Biotechnology. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Medigen Biotechnology Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Medigen Biotechnology. The current macd is -0.72774008.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Medigen price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Medigen. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Medigen price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Medigen Biotechnology Daily Moving Average Convergence/Divergence (MACD) ChartMedigen Biotechnology Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Medigen Biotechnology. The current adx is 17.28.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Medigen shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Medigen Biotechnology Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Medigen Biotechnology. The current sar is 37.35.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Medigen Biotechnology Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Medigen Biotechnology. The current rsi is 46.45. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Medigen Biotechnology Daily Relative Strength Index (RSI) ChartMedigen Biotechnology Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Medigen Biotechnology. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Medigen price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Medigen Biotechnology Daily Stochastic Oscillator ChartMedigen Biotechnology Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Medigen Biotechnology. The current cci is 2.24683036.

Medigen Biotechnology Daily Commodity Channel Index (CCI) ChartMedigen Biotechnology Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Medigen Biotechnology. The current cmo is -1.55231347.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Medigen Biotechnology Daily Chande Momentum Oscillator (CMO) ChartMedigen Biotechnology Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Medigen Biotechnology. The current willr is -49.33333333.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Medigen is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Medigen Biotechnology Daily Williams %R ChartMedigen Biotechnology Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Medigen Biotechnology.

Medigen Biotechnology Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Medigen Biotechnology. The current atr is 1.2172221.

Medigen Biotechnology Daily Average True Range (ATR) ChartMedigen Biotechnology Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Medigen Biotechnology. The current obv is 4,766,573.

Medigen Biotechnology Daily On-Balance Volume (OBV) ChartMedigen Biotechnology Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Medigen Biotechnology. The current mfi is 39.15.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Medigen Biotechnology Daily Money Flow Index (MFI) ChartMedigen Biotechnology Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Medigen Biotechnology.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-10-31STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-03STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-06ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-08ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-23STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-25STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-26MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Medigen Biotechnology Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Medigen Biotechnology based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.449
Ma 20Greater thanMa 5039.328
Ma 50Greater thanMa 10040.726
Ma 100Greater thanMa 20045.401
OpenGreater thanClose38.850
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Medigen with someone you think should read this too:
  • Are you bullish or bearish on Medigen? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Medigen? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Medigen Biotechnology

I send you an email if I find something interesting about Medigen Biotechnology.


Comments

How you think about this?

Leave a comment

Stay informed about Medigen Biotechnology.

Receive notifications about Medigen Biotechnology in your mailbox!